US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
pharma · Advanced Solid Tumor · Hepatocellular Carcinoma
Coherus Oncology
Coherus Oncology drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, US HQ
2010 Founded
212 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, US
- Founded
- 2010
- Employees
- 212
- Programs
- 25
- Drugs
- 11
- Patents
- 73
Coherus Oncology pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Coherus Oncology drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Coherus Oncology in public FDA and regional records.
-
Development asset linked to Coherus Oncology in public FDA and regional records.
-
Development asset linked to Coherus Oncology in public FDA and regional records.
-
dupilumab
Dermatologicals (D11)US regulatory status: approved. Molecular target: Interleukin-4 receptor subunit alpha.
- Target
- Interleukin-4 receptor subunit alpha
- Mechanism
- Interleukin-4 receptor subunit alpha antagonist
-
etanercept
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
Development asset linked to Coherus Oncology in public FDA and regional records.
-
toripalimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Coherus Oncology's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
Development asset linked to Coherus Oncology in public FDA and regional records.